Zydus Lifesciences up ~2% after Novartis ALS program exit
Bernstein said Novartis’ discontinuation of an experimental ALS drug improved the outlook for Zydus Lifesciences’ Usnoflast. Zydus Lifesciences shares rose nearly 2% in Friday’s trade.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.